{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000060","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.506472+00:00","generated_at":"2026-06-07T04:08:39.261889+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aprea Therapeutics provides 2024 pipeline update: ATRN-119 dose escalation ongoing, IND for APR-1051 expected Q1 2024","bullets":["Phase 1/2a trial of ATRN-119 continues; two patients achieved stable disease at 50 mg and 200 mg doses.","Dose-limiting toxicity period for 350 mg cohort completed; RP2D expected H2 2024.","IND submission for next-gen WEE1 inhibitor APR-1051 being finalized; FDA clearance expected Q1 2024.","Preclinical data for APR-1051 show improved selectivity and reduced off-target effects vs other WEE1 inhibitors.","Company to hold investor meetings at LifeSci Partners Corporate Access Event on Jan 10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000060","json":"https://secwatch.observer/filing/0001558370-24-000060.json","markdown":"https://secwatch.observer/filing/0001558370-24-000060.md","text":"https://secwatch.observer/filing/0001558370-24-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/0001558370-24-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024000060/apre-20240104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:08:39.261889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}